Curtailing the AIDS pandemic.

The decision not to go forward with phase III efficacy trials of human immunodeficiency virus type-1 (HIV-1) vaccines in the United States in 1994 (Research News, 17 Dec. 1993, p. 1820) was based in part on the paucity of data suggesting that current vaccine candidates would provide sterilizing

[1]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[2]  C. Macken,et al.  Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant , 1997, Nature Medicine.

[3]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[4]  B. Moss,et al.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara , 1996, Journal of virology.

[5]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[6]  J. Mullins,et al.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine , 1996, Journal of virology.

[7]  J S Koopman,et al.  Assessing HIV vaccine effects. , 1995, American journal of epidemiology.

[8]  S. Nachman,et al.  Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Scandella,et al.  Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. , 1994, AIDS research and human retroviruses.

[10]  J. Heeney,et al.  HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. , 1994, Vaccine.